4D Molecular Therapeutics Newsroom

We're Hopeful That 4D Molecular Therapeutics (NASDAQ:FDMT) Will Use Its Cash Wisely

Yahoo FinanceOct 30 22:26

4D Molecular Therapeutics Downgraded at Cantor Following Wet AMD Asset Data

Seeking AlphaSep 24 01:41 · Ratings

4D Molecular Therapeutics Analyst Ratings

BenzingaSep 24 00:55 · Ratings

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

GlobeNewswireSep 23 20:00

Cantor Fitzgerald Downgrades 4D Molecular Therapeutics(FDMT.US) to Hold Rating

Cantor Fitzgerald analyst Joshua Schimmer downgrades $4D Molecular Therapeutics(FDMT.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 52.2% and a total average

Futu NewsSep 23 19:31 · Ratings

Cantor Fitzgerald Downgrades 4D Molecular Therapeutics to Neutral From Overweight

MT NewswiresSep 23 19:16

A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $82

On Sep 20, major Wall Street analysts update their ratings for $4D Molecular Therapeutics(FDMT.US)$, with price targets ranging from $36 to $82.Goldman Sachs analyst Salveen Richter maintains with a

Futu NewsSep 20 21:00 · Ratings

4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate

BenzingaSep 20 02:34

4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesSep 20 00:01 · Ratings

A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $36 to $79

On Sep 19, major Wall Street analysts update their ratings for $4D Molecular Therapeutics(FDMT.US)$, with price targets ranging from $36 to $79.BofA Securities analyst Tazeen Ahmad maintains with a

Futu NewsSep 19 21:00 · Ratings

Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Satellos Bioscience (MSCLF)

TipRanksSep 19 18:30 · Ratings

Express News | 4D Molecular Therapeutics Inc : Leerink Partners Cuts Target Price to $36 From $40

BreakingsSep 19 10:53

4d Molecular Therapeutics Executive Sells $8.2k in Stock

InvestingSep 19 05:50

4D Molecular Therapeutics Reveals 'Robust, Durable Clinical Activity' in Wet AMD Drug Trial

MT NewswiresSep 19 05:06

Express News | 4D Molecular Therapeutics : Expect to Initiate 4Front-1 in Q1 2025

BreakingsSep 19 04:12

4DMT Highlights Clinical Activity For 4D-150 And Design Of 4FRONT Phase 3 Program At 4D-150 Wet AMD Development Day

BenzingaSep 19 04:07

RBC Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $40

RBC Capital analyst Lisa Walter maintains $4D Molecular Therapeutics(FDMT.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 33

Futu NewsSep 11 19:33 · Ratings

4D Molecular Therapeutics (FDMT) Receives a Buy From RBC Capital

TipRanksSep 11 19:06 · Ratings

The Latest Analyst Ratings For 4D Molecular Therapeutics

BenzingaSep 10 02:01 · Ratings

Cantor Fitzgerald Reiterates Overweight on 4D Molecular Therapeutics

BenzingaSep 10 01:03